CPT 0082U: NextGen Precision™ Urine Drug Interaction Screening

CPT code 0082U identifies a Proprietary Laboratory Analyses (PLA) test — NextGen Precision™ from Precision Diagnostics — a presumptive urine drug test that screens instrumentally for the severity of possible interactions among 90+ drugs, metabolites, and other substances. As a PLA code, 0082U maps to a single manufacturer-specific test and is used when reporting that specific assay.

This code matters nationally as PLA-designated tests are increasingly used in precision toxicology and medication management, creating distinct billing flows and coverage considerations compared with non-proprietary laboratory assays. Key payers discussed in this profile include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Payer coverage policies and reimbursement practices for PLA tests vary by plan and often hinge on medical necessity criteria and documentation of clinical utility.

Readers will find a concise overview of clinical context (presumptive urine drug interaction screening), typical service and site of service, and the payers addressed. The report summarizes benchmarks where available, notes policy and coding considerations relevant to PLA tests, and provides context for coding and claims submission. Data not available in the input will be noted as such in relevant sections.

Billing Code Overview

CPT code 0082U is a Proprietary Laboratory Analyses (PLA) code for the NextGen Precision™ test from Precision Diagnostics. The code describes a presumptive drug test that uses instrumented chemistry analyzers to analyze a urine specimen for the severity of possible interactions among 90 or more drugs, drug breakdown products, or other substances.

Service Type: Proprietary laboratory drug interaction screening using instrumented chemistry analyzers

Typical Site of Service: Clinical laboratory or outpatient laboratory setting where urine specimens are collected and analyzed

Clinical Context

A typical patient is a 45-year-old outpatient referred by a primary care physician or pain management specialist for a urine-based presumptive drug interaction screen after a medication review identified polypharmacy risks. The patient presents to an outpatient laboratory or hospital outpatient collection center; a urine specimen is collected under standard chain-of-custody or routine specimen handling depending on clinic policy. The specimen is analyzed by an instrumented chemistry analyzer using the NextGen Precision™ assay to screen for severity of possible interactions among 90+ drugs, metabolites, or substances. Results are reported to the ordering clinician to inform medication reconciliation, opioid stewardship, substance use evaluation, or adverse drug reaction assessment. Typical workflow steps: order placed by clinician, patient check-in at outpatient laboratory or hospital outpatient department, urine specimen collected and labeled, specimen received and processed in the laboratory performing the NextGen Precision™ test, instrumented chemistry analysis performed, result interpretation and report generated, clinician reviews results and documents findings in the patient medical record.

Coding Specifications

Modifier	Description	When to Use
`00`	No modifier; standard reporting	Use when no additional modifier is necessary and the service is reported as usual.

Taxonomy Code	Specialty	Notes
`208D00000X`	Clinical Laboratory Services	Most common specialty performing instrumented chemistry and proprietary PLA testing.
`207Q00000X`	Anatomic and Clinical Pathology	Pathologists who may oversee laboratory testing and result interpretation.
`208000000X`	Diagnostic Laboratory	Laboratories performing high-complexity and instrumented assays.
`213E00000X`	Pain Management	Clinicians ordering drug interaction and monitoring panels for medication safety.
`207L00000X`	Medical Toxicology	Specialists who may order and interpret complex drug interaction testing.

Related Diagnoses

ICD-10 Code	Description	Clinical Relevance
`F11.20`	Opioid dependence, uncomplicated	Opioid-prescribed patients may undergo interaction screening to assess co-ingested substances and metabolic interactions.
`F12.20`	Cannabis dependence, uncomplicated	Screening can detect cannabis metabolites that may interact with prescribed medications.
`T43.6X1A`	Poisoning by psychostimulants, accidental (initial encounter)	Used when suspected adverse effects or interactions from stimulants prompt broad interaction testing.
`R78.89`	Other specified abnormal findings of blood chemistry	Abnormal chemical findings may prompt expanded drug interaction testing to explain lab abnormalities.
`Z79.891`	Long term (current) use of opiate analgesic	Patients on chronic opioids are commonly screened for potential interactions and concomitant substance use.

Related CPT Codes

CPT Code	Description	Relationship to This Procedure
`81002`	Urinalysis, non-automated, without microscopy	Often performed concurrently to assess urine specimen adequacy before sending for PLA testing.
`82570`	Drug assay, multiple drug classes (e.g., immunoassay), qualitative or semi-quantitative, urine, 1–8 drug classes	A preliminary immunoassay screen that may precede or complement the more extensive proprietary PLA analysis.
`80307`	Drug test(s), presumptive, any number of drug classes; any number of drug classes	General CPT for presumptive drug testing that can be used alongside specific PLA codes when broader screening is performed.
`84156`	Drug assay, of a specific drug or metabolite, quantitative	Quantitative confirmatory assays that may be ordered after a presumptive NextGen Precision™ result indicates potential interactions.
`80053`	Comprehensive metabolic panel	Routine chemistry panel that may be ordered with drug interaction testing to assess organ function relevant to drug metabolism.

OpenPayer

Summary & Overview